Bush nominates Crawford to vacant FDA commissioner post

Share this article:
President Bush nominated Lester Crawford to serve as commissioner of the FDA.
Crawford currently serves as acting commissioner of the agency and has run the FDA since the departure of Mark McClellan, who moved to the Centers for Medicare and Medicaid Services in March 2004.
Crawford also served as acting FDA commissioner from February to November 2002.
The Senate must confirm the nomination before Crawford can officially assume the role of commissioner -- a position that has been vacant for nearly a year amid concerns about the safety of drugs on the market.
Crawford, 66, earned a degree as a veterinarian from Auburn University and a Ph. D. in pharmacology from the University of Georgia. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...